List of RMs MK0616 / Enlicitide decanoate
Enlicitide (formerly MK-0616) is an investigational, once-daily oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) developed by Merck. Phase 3 trials (CORALreef program) show it significantly lowers LDL cholesterol by approximately 60% in adults with hypercholesterolemia, offering a potential oral alternative to injectable PCSK9 inhibitors.
We supply the list of RMs commercial below
(S)-2-Methylpyrrolidine-2-carboxylic acid Hcl | 1508261-86-6 |
N-Boc-O-methyl-L-tyrosine [Boc-Tyr(Me)-OH] | 53267-93-9 |
5-Fluoro-L-tryptophan | 16626-02-1 |
CBZ-trans-3-Hydroxy-L-proline | 62182-54-1 |
L-3-Cyanophenylalanine | 57213-48-6 |
(2S)-2-amino-3-(5-fluoro-1-prop-2-enylindol-3-yl)propanoic acid | 3067192-74-6 |
Boc-Tyr(Me)-aMePro-OH | 2618723-51-4 |
Please first Loginlater ~